1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Drugs In Development, 2022, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 25, 301, 267, 6, 24, 197, 42 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 12, 14, 1, 25, 4 and 1 molecules, respectively.
Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Head And Neck Cancer - Overview
- Head And Neck Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Head And Neck Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Head And Neck Cancer - Companies Involved in Therapeutics Development
- Head And Neck Cancer - Drug Profiles
- Head And Neck Cancer - Dormant Projects
- Head And Neck Cancer - Discontinued Products
- Head And Neck Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Head And Neck Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Head And Neck Cancer - Dormant Projects, 2022
- Head And Neck Cancer - Discontinued Products, 2022
- Head And Neck Cancer - Discontinued Products, 2022 (Contd..1)
- Number of Products under Development for Head And Neck Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2A Pharma AB
- 4D Pharma Plc
- 4SC AG
- A2 Biotherapeutics Inc
- Aadi Bioscience Inc
- ABBA Therapeutics AG
- AbbVie Inc
- Accendatech Co Ltd
- Achilles Therapeutics Plc
- Actuate Therapeutics Inc
- Adagene Suzhou Ltd
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Advanced Accelerator Applications SA
- Advaxis Inc
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Affimed GmbH
- AGC Biologics SpA
- Agenus Inc
- AilseVax Ltd
- Akeso Inc
- Alkermes Plc
- Alligator Bioscience AB
- Alphageneron-Pharmaceuticals Inc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- ALX Oncology Holdings Inc
- Ambrx Biopharma Inc
- amcure GmbH
- Amgen Inc
- Aminex Therapeutics Inc
- AnBogen Therapeutics
- ANP Technologies Inc
- Anteris Technologies Ltd
- AP Biosciences Inc
- Apexigen Inc
- Apollomics Inc
- Arch Oncology Inc
- Arcus Biosciences Inc
- Argenx SE
- Ascenta Therapeutics Inc
- Ascentage Pharma Group Inc
- Ascentage Pharma Group International
- Asclepiumm Taiwan Co Ltd
- Asher Biotherapeutics Inc
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Athenex Inc
- Atreca Inc
- Aura Biosciences Inc
- Aurigene Discovery Technologies Ltd
- Avacta Life Sciences Ltd
- Avalon GloboCare Corp
- AVEO Pharmaceuticals Inc
- Avesthagen Ltd
- Aveta Biomics Inc
- Avvinity Therapeutics Ltd
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beijing Biostar Technologies Ltd
- Beijing Corregene Biotechnology Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- Beijing Weiyuan Likang Biological Technology Co
- Bicara Therapeutics Inc
- Bicycle Therapeutics Plc
- Bika Biotechnology Guanzhou Co Ltd
- Bio-Synectics Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioCurity Pharmaceuticals Inc
- Biohaven Pharmaceutical Holding Company Ltd
- BioLineRx Ltd
- Biomics Biotechnologies Co Ltd
- Biomimetix JV LLC
- Biomunex Pharmaceuticals
- BioNTech SE
- Biosion Inc
- BioSyngen Pte Ltd
- Biotheus Inc
- Bioven Group
- Bioviz Technologies Pvt Ltd
- BJ Bioscience Inc
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- BP InnoMed Ltd
- BrightPath Biotherapeutics Co Ltd
- Bristol-Myers Squibb Co
- Brooklyn ImmunoTherapeutics Inc
- Byondis BV
- Calico Life Sciences LLC
- Calidi Biotherapeutics Inc
- Calithera Biosciences Inc
- CanBas Co Ltd
- Cancer Therapeutics Laboratories Inc
- Canget BioTekpharma LLC
- Cantargia AB
- CarboMimetics
- Cardiff Oncology Inc
- CDR-Life Inc
- CEL-SCI Corp
- Celcuity Inc
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Cello Therapeutics Inc
- Celprogen Inc
- Celularity Inc
- Centrymed Pharmaceutical Inc
- Centurion BioPharma Corp
- Checkpoint Therapeutics Inc
- Chengdu Wonho Biology Engineering Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- China Immunotech Co Ltd
- Chinook Therapeutics Inc
- Codiak BioSciences Inc
- Coherent Biopharma
- Compugen Ltd
- Cortexyme Inc
- Corvus Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cue Biopharma Inc
- Curevac NV
- Curigin Co Ltd
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- Cyclica Inc
- Cyteir Therapeutics Inc
- CytImmune Sciences Inc
- Cytodyn Inc
- CytomX Therapeutics Inc
- Cytovation AS
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- DNJ Pharma Inc
- Dracen Pharmaceuticals Inc
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Duet Therapeutics Inc
- Dyadic International Inc
- Edison Oncology Holding Corp
- eFFECTOR Therapeutics Inc
- Eisai Co Ltd
- Elevation Oncology Inc
- Eli Lilly and Co
- Elicio Therapeutics Inc
- Elixiron Immunotherapeutics Inc
- Elpiscience Biopharma Ltd
- ENB Therapeutics LLC
- Enhancedbio Inc
- Enzene Biosciences Ltd
- EpicentRx Inc
- EpimAb Biotherapeutics Inc
- EpiThany Inc
- Epizyme Inc
- Erasca Inc
- eTheRNA Immunotherapies NV
- Euclises Pharmaceuticals Inc
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- Flow Pharma Inc
- Fochon Pharmaceutical Ltd
- Forbius
- Frezent Biological Solutions Inc
- Fujifilm Holdings Corp
- FUJIFILM Toyama Chemical Co Ltd
- Fusion Pharmaceuticals Inc
- G&E Herbal Biotechnology Co., Ltd.
- Galectin Therapeutics Inc
- Galera Therapeutics Inc
- Geneius Biotechnology Inc
- Genelux Corp
- Genentech USA Inc
- GeneQuantum Healthcare Suzhou Co Ltd
- Genexine Inc
- GenFleet Therapeutics (Shanghai) Inc
- GenKyoTex SA
- Genmab AS
- Genocea Biosciences Inc
- Genome & Co
- Genor BioPharma Co Ltd
- GeoVax Labs Inc
- Gilead Sciences Inc
- GLG Pharma SA
- Gliknik Inc
- Glycomantra Inc
- GlycoMira Therapeutics Inc
- Glycostem Therapeutics BV
- Glycotope GmbH
- GO Therapeutics Inc
- GSK plc
- GT Biopharma Inc
- Guangzhou Bairui Biomedical Technology Co Ltd
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Doublle Bioproduct Inc
- Guangzhou Sinogen Pharmaceutical Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Handok Inc
- Hangzhou DAC Biotech Co Ltd
- Hangzhou Zenshine Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- HDT Bio Corp
- Hercules Pharmaceuticals BV
- Hibercell Inc
- HiFiBiO Therapeutics Inc
- Highlight Therapeutics SL
- Hillstream BioPharma Inc
- HitGen Inc
- Hookipa Pharma Inc
- Horizon Therapeutics Plc
- HRYZ (ShenZhen) Biotech Co
- Huabo Biopharm (Shanghai) Co Ltd
- Hummingbird Bioscience Pte Ltd
- HylaPharm
- I-Mab
- Ideaya Biosciences Inc
- Idera Pharmaceuticals Inc
- IGM Biosciences Inc
- Ikena Oncology Inc
- ImCheck Therapeutics SAS
- Immatics NV
- Immix BioPharma Inc
- Immodulate Pharma AB
- ImmuneOnco Biopharmaceuticals
- ImmuneSensor Therapeutics Inc
- ImmunityBio Inc
- Immunocore Limited
- Immunogenesis Inc
- Immunome Inc
- Immunomic Therapeutics Inc
- Immutep Ltd
- Immvira Co Ltd
- Imugene Ltd
- IMV Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Inhibrx Inc
- Inmune Bio Inc
- InnoCare Pharma Ltd
- InnoMab Pte Ltd
- Innovative Cellular Therapeutics Co
- Innovene
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- Instil Bio Inc
- ISU ABXIS Co Ltd
- iTeos Therapeutics Inc
- Jacobio Pharmaceuticals Group Co Ltd
- Janux Therapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Vcare PharmaTech Co Ltd
- Jiangxi Jemincare Group Co Ltd
- Jiangxi Qingfeng Pharmaceutical Co Ltd
- Jina Pharmaceuticals Inc
- Johnson & Johnson
- Joint Biosciences Ltd
- Jounce Therapeutics Inc
- Jubilant Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kiadis Pharma NV
- Kineta Inc
- Komipharm International Co Ltd
- Kymab Ltd
- Kyowa Kirin Co Ltd
- L&L Biopharma Co Ltd
- L.E.A.F. Pharmaceuticals LLC
- Laboratoires Pierre Fabre SA
- LATITUDE Pharmaceuticals Inc
- Leucid Bio Ltd
- Lidds AB
- LIfT BioSciences Ltd
- LightOx Ltd
- Linnaeus Therapeutics Inc
- Lion TCR Pte Ltd
- LipoSeuticals Inc
- Luminus Biosciences Inc
- Luye Pharma Group Ltd
- Luzitin SA
- Lycera Corp
- LynkCell Inc
- Lytix Biopharma AS
- Lyvgen Biopharma Ltd
- Mabion SA
- Mabpharm Ltd
- MacroGenics Inc
- MAIA Biotechnology Inc
- ManysmarT Therapeutics Inc
- Mekanistic Therapeutics LLC
- Memgen Inc
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Merus NV
- Metaclipse Therapeutics Corp
- Millennium Pharmaceuticals Inc
- MiNK Therapeutics Inc
- Mirati Therapeutics Inc
- MiRecule Inc
- MiReven Pty Ltd
- Mitsubishi Tanabe Pharma Corp
- Moderna Inc
- Modra Pharmaceuticals BV
- Molecular Partners AG
- Molecular Targeting Technologies Inc
- Molecular Templates Inc
- Moleculin Biotech Inc
- Morphogenesis Inc
- Multitude therapeutics Inc
- MultiVir Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nanjing Sanhome Pharmaceutical Co Ltd
- NanoCarrier Co Ltd
- NantBioScience Inc
- Natco Pharma Ltd
- Nektar Therapeutics
- Neonc Technologies Inc
- NeoTX Therapeutics Ltd
- Neumedicines Inc
- NexImmune Inc
- NextCure Inc
- NGM Biopharmaceuticals Inc
- NKGen Biotech Inc
- Novartis AG
- Noxopharm Ltd
- Nubiyota LLC
- Nurix Therapeutics Inc
- Nuvectis Pharma Inc
- Nykode Therapeutics ASA
- Obsidian Therapeutics Inc
- Ocellaris Pharma Inc
- OncoResponse Inc
- Oncorus Inc
- OncoSec Medical Inc
- Oncotelic Therapeutics Inc
- Oncovir Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- Orgenesis Inc
- Ovensa Inc
- Oxford Vacmedix UK Ltd
- Pact Pharma Inc
- Palleon Pharmaceuticals Inc
- Papivax LLC
- PCI Biotech Holding ASA
- PDS Biotechnology Corp
- Pfizer Inc
- Pharma Mar SA
- Philogen SpA
- Phio Pharmaceuticals Corp
- Pionyr Immunotherapeutics Inc
- PlantForm Corp
- Plexxikon Inc
- Plus Therapeutics Inc
- Poseida Therapeutics Inc
- Potenza Therapeutics Inc
- Precigen Inc
- Precision Biologics Inc
- Prelude Therapeutics Inc
- PRISM Pharma Co Ltd
- Privo Technologies Inc
- Promontory Therapeutics Inc
- Protheragen Inc
- Provectus Biopharmaceuticals Inc
- PsiOxus Therapeutics Ltd
- Psivac Ltd
- Puma Biotechnology Inc
- Purple Biotech Ltd
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Qrono Inc
- Quadriga BioSciences Inc
- Qwixel Therapeutics LLC
- RaQualia Pharma Inc
- Refuge Biotechnologies Inc
- Regeneron Pharmaceuticals Inc
- Relay Therapeutics Inc
- RemeGen Co Ltd
- Repare Therapeutics Inc
- Repertoire Immune Medicines Inc
- Replimune Ltd
- Reven Holdings Inc
- Ribon Therapeutics Inc
- RS Research
- Rubius Therapeutics Inc
- Sanofi
- Sareum Holdings Plc
- Sathgen Biotech
- Scancell Holdings Plc
- Scholar Rock Inc
- Seagen Inc
- Secura Bio Inc
- SEEKYO Therapeutics
- Sensei Biotherapeutics Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai Affinity Biomedical Technology Co Ltd
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Gencells Therapeutics Co Ltd
- Shanghai GeneChem Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Institute of Biological Products Co Ltd
- Shanghai Jing Ze Biotechnology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Miracogen Inc
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shanghai Yuansong Biotechnology Co Ltd
- Shattuck Labs Inc
- Shenghe (China) Biopharmaceutical Co Ltd
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Theravectys SA
- TILT Biotherapeutics Ltd
- Tizona Therapeutics Inc
- Tmunity Therapeutics Inc
- TOLREMO Therapeutics AG
- TOT Biopharm Co Ltd
- Touchlight Genetics Ltd
- Transcenta Holding Ltd
- Transgene SA
- Treadwell Therapeutics Inc
- TScan Therapeutics Inc
- Tuhura Biopharma Inc
- Turning Point Therapeutics Inc
- Turnstone Biologics Inc
- Tvardi Therapeutics Inc
- Tyme Inc
- UbiVac LLC
- UCB SA
- Ultimovacs AS
- United Immunity Co Ltd
- Vaccinex Inc
- VasGene Therapeutics Inc
- Vault Pharma Inc
- Vaximm AG
- VCN Biosciences SL
- Vectorite Biomedical Inc
- Venus Remedies Ltd
- Versameb AG
- Viracta Therapeutics Inc
- Virion Therapeutics LLC
- Virocure Inc
- VM Discovery Inc
